A practical reference on reference standard: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-29. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
Conditions in the predominant agricultural sector kept deteriorating between 1929 and 1939, which resulted in rural unrest and a progressive radicalization of the Polish peasant movement that became increasingly inclined toward militant anti-state activities. It was firmly repressed by the authorities. According to Norman Davies, the failures of the Sanation government (combined with the objective economic realities) caused a radicalization of the Polish masses by the end of the 1930s, but he warns against drawing parallels with the incomparably more oppressive Nazi Germany or the Stalinist Soviet Union.
Channel-switching is the action of consumers switching from one type of channel intermediary to a different type of intermediary for their purchases. Examples include switching from brick-and-mortar stores to online catalogues and e-commerce providers; switching from grocery stores to convenience stores or switching from top tier department stores to mass market discount outlets. A number of factors have led to an increase in channel switching behaviour; the growth of e-commerce, the globalization of markets, the advent of category killers (such as Officeworks and Kids 'R Us) as well as changes in the legal or statutory environment. For instance, in Australia and New Zealand, following a relaxation of laws prohibiting supermarkets from selling therapeutic goods, consumers have gradually switched away from pharmacies and toward supermarkets for the purchase of minor analgesics, cough and cold preparations and complementary medicines such as vitamins and herbal remedies. For the consumer, channel switching offers a more diverse shopping experience, which may concern some sellers by its potential to erode market share. Evidence of channel switching can suggest that disruptive forces are at play, and that consumer behaviour is undergoing fundamental changes. A consumer may be prompted to switch channels when the product or service can be found at cheaper prices, when superior models become available, when a wider range is offered, or simply because it is more convenient to shop through a different channel (e.g. online or one-stop shopping).
This also addresses the side effects that occur when using opioid agents. The results of this study showed that pain-reducing effects were observed with all three methods of administration. The drugs gabapentin and pregabalin have long since been used for the treatment of neuropathic pain conditions. The mechanism behind the effectiveness of these drugs is not fully known. However, gabapentin and pregabalin were demonstrated to have supraspinal-mediated analgesic effects after peripheral nerve injury. This is due to the noradrenergic pain inhibitory system that is employed by these drugs, coupled with spinal receptors that produce analgesic effects. The results of this study indicate that ICV injection of these drugs decreases thermal and mechanical hypersensitivity in a murine chronic pain model that has partial ligation of the sciatic nerve.
=== Estrogens === The estrogen diethylstilbestrol (DES) is occasionally used to treat prostate cancer through suppression of testosterone production. It was previously used in the treatment of breast cancer, but has been replaced by more effective and less toxic agents. Estrace is an estrogen which was also formerly used for antiandrogen therapy of prostate cancer. Polyestradiol phosphate is a long-acting derivative of estradiol that is applied as an intramuscular injection.
Sources: en.wikipedia.org
Tanzi, RE; Petrukhin, K; Chernov, I; Pellequer, JL; Wasco, W; Ross, B; Romano, DM; Brzustowicz, LM; Devoto, M; Peppercorn, J; Bush, AI; Sternlieb, I; Pirastu, M; Gusella, JF; Evgrafov, O; Penchaszadeh, GK; Honig, B; Edelman, IS; Soares, MB; Scheinberg, IH; Gilliam, TC (1993). "Identification of the Wilson's disease gene: A copper transporting ATPase with homology to the Menke's disease gene". Nature Genetics. 5 (4): 344–350. Bibcode:1993NaGen...5..344T. doi:10.1038/ng1293-344. PMID 8298641. S2CID 610188. Levy-Lahad, E; Wasco, W; Poorkaj, P; Romano, DM; Oshima Jm, Pettingell WH; Yu, C; Jondro, PD; Schmidt, SD; Wang, K; Crowley, AC; Fu, Y-H; Guenette, SY; Galas, D; Nemens, E; Wijsman, EM; Bird, TD; Schellenberg, GD; Tanzi, RE (1995). "Candidate gene for the chromosome 1 familial Alzheimer's disease locus". Science. 269 (5226): 973–977. Bibcode:1995Sci...269..973L. doi:10.1126/science.7638622. PMID 7638622. S2CID 27296868. Bertram, L; Blacker, D; Mullin, K; Keeney, D; Jones, J; Basu, S; Yhu, S; McInnis, M; Go, R; Vekrellis, K; Selkoe, D; Saunders, A; Tanzi, RE (2000). "Evidence for genetic linkage of Alzheimer's disease to chromosome 10q". Science. 290 (5500): 2302–2303. Bibcode:2000Sci...290.2302B. doi:10.1126/science.290.5500.2302. PMID 11125142. Bertram, L; Hiltunen, M; Parkinson, M; Ingelsson, M; Lange, C; Ramasamy, K; Mullin, K; Menon, R; Sampson, AJ; Hsiao, MY; Elliott, KJ; Moscarillo, T; Hyman, BT; Wagner, SL; Becker, KD; Blacker, D; Tanzi, RE (2005). "Family-based association between Alzheimer's disease and variants in UBQLN1". N. Engl. J. Med. 352 (9): 884–894.
== Function == As well as C. maenas, CCAP has cardioacceleratory properties in Manduca sexta and Drosophila melanogaster; it is a highly conserved protein found in species as diverse as moths and fruit flies in addition to the crustacean it was originally identified in. Under specific conditions, CCAP has also been shown to induce cardiac reversal in M. sexta and D. melanogaster. Since CCAP was first identified and its possible role suggested, it has been proven it serves many other functions. It regulates release of adipokinetic hormone during sustained flight in L. migratoria. It is also important in metabolism and digestion in other species; CCAP is involved as a hormone in the cockroach Periplaneta americana by upregulating digestive hormones after the insect has fed on nutritional matter. In the crab Cancer borealis CCAP controls passage of food through the foregut by modulating the stomatogastric ganglion's pyloric rhythm. This suggests CCAP is involved primarily in movement of food along the gut, facilitating digestion by secretion of digestive hormones and increasing flow of blood. The effects of CCAP on the reproductive organs of females of the species L. migratoria have also been studied. The peptide stimulates the contraction of the oviducts and spermatheca. There is no CCAP or CCAP-like immunoreactivity shown in the oviduct or the nerves innervating the oviduct so it is probable that CCAP acts as a neurohormone to perform these functions. CCAP is one of several peptides and hormones to be involved in the moulting process of crustaceans and insects.
== Education and academic career == Bhushan began his education in his native India, completing his undergraduate and master's degrees from the University of Jodhpur. He received his Ph.D. in chemistry (working on structure elucidation of natural products isolated from certain desert plants) in 1978 at the University of Jodhpur. Bhushan joined as a lecturer at the University of Roorkee (now Indian Institute of Technology Roorkee, India) in 1979 and was later selected for the position of full professor of chemistry in 1996 and served there till retirement in 2018.
== Contraindications == People with chronic kidney disease and large total body surface area (TBSA) burns should not use nitrofurazone, as topical preparations commonly contain polyethylene glycol, which is readily absorbed through the skin. Rapid absorption of the medication induces increased serum osmolalities and anion gap, leading to death. Symptoms are similar to ethylene glycol poisoning, in that increased serum calcium levels occur concurrently with decreased ionized calcium. Nitrofurans have been found in honey, meat and seafood. In people who have glucose-6-phosphate dehydrogenase deficiency (G-6-PD deficiency), ingestion of fish, poultry, or other foodstuff that has been treated with nitrofurans, will likely suffer from hemolysis of red blood cells as a result of eating the contaminated food.
== Gameplay == Day of Defeat is a multiplayer first-person shooter that simulates squad-level infantry combat between the adversaries of World War II's European Theatre; the Allies and the Axis powers. Players can choose to join either the Allied or Axis armies, with the Allies including the United States or Great Britain and the Axis including Germany. A round begins with two opposing teams starting simultaneously in their respective spawn area of a map, both acting towards the goal of achieving their respective objectives whilst preventing the enemy team from accomplishing theirs. A round ends when one team accomplishes all of its objectives, with that team claiming victory. Eventually, the game ends with the expiration of a set time limit, and the team with the most objectives achieved is the winning team regardless of kills or casualties, except in the case of both teams having not achieved any objectives or having achieved the same number of objectives. Weaponry in the game attempts to realistically portray those that would be found in World War II, and the gameplay reflects this aesthetic choice. Recoil can be heavy and the game does not allow the player to fire while running or jumping. The game also features a stamina bar, preventing the player from sprinting for long periods of time and forcing them to actively conserve energy.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.